Q-omics provides the consensus-scored MIR181D profile across patient tissues and cancer cell-line models. MIR181D expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR181D is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR181D RNA expression shows 11,031 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LUSC, and UVM as cancer lineages where MIR181D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR181D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR181D survival associations across molecular data types. MIR181D RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR181D RNA expression–survival associations across cancer types. High MIR181D expression shows unfavorable associations in ACC, READ and KIRP, but favorable associations in BRCA, LAML and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR181D RNA expression.
This table summarizes MIR181D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR181D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR181D shows lower tumor expression in LUSC, BRCA and UCEC and higher tumor expression in HNSC and COAD. The LUSC box plot shows higher MIR181D RNA expression in normal versus tumor tissue (log2 FC = −0.179, t-test p = .002).
This table shows molecular features associated with MIR181D in patient tissues and cancer cell lines. In patient samples, MIR181D shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
